期刊文献+

反相高效液相色谱法测定阿立哌唑血药浓度 被引量:3

Determineing the Serum Soncentration of Aripiprazole by RP-HPLC
下载PDF
导出
摘要 目的建立测定人血清中阿立哌唑浓度的RP—HPLC法。方法以Shim—pack VP—ODSC18(150×4.6mmI.D.)为色谱柱,流动相为甲醇-乙腈-水(80:190:255),其中加5ml正丁胺调整峰型,并用醋酸将PH值调到5.5,流速为1.0ml/min,检测波长257nm,以乙醚为提取剂。结果阿立哌唑的高(800ng/ml)、中(400ng/ml)、低(200ns/ml)3个浓度的提取回收率分别为100.63%,100.38%,93.84%;分析方法的最低定量限为25ng/ml。线性范围为25—800ng/ml,回归方程为Y=290.287X-5.65288,r=0.9995(n=6)。结论该方法灵敏、准确、成本低、专一性强,可满足临床治疗过程中的阿立哌唑血药浓度测定需求。 Objective To establish a method for determining the serum concentration of aripiprazole by RP - HPLC. Methods The residues were analyzed in a Shim-pack VP- ODS C18 (150 ×4.6 mm I. D. ) with the mobile phase consisted of methanol and acetonitrile and water(80: 190:255 ), add 5ml n - butylamine adjusting peak type, the pH to 5.5 with acetic acid, and the flow rate was 1 ml/min, the detection wave length was at 257 nm, extraction solvent was ethyl ether. Results The average recoveries for aripiprazole were 100.63%, 100.38% and 93.84% respectively. The limits of quantitation for aripiprazole was 25 ng/ml. The calibration curves for aripiprazole had good linearity, Y = 290. 287X - 5. 65288, r = 0. 9995 ( n = 6), over the range of 25 - 800 ng/ml. Conclusion The method is sensitive, accurate,low cost, high specificity, and can meet the needs of aripiprazole blood concentration of clinical treatment in the determination of demand.
出处 《中国健康心理学杂志》 2014年第2期187-188,共2页 China Journal of Health Psychology
关键词 阿立哌唑 血药浓度 反相高效液相色谱法 精神药理学 Aripiprazole Serum concentration RP - HPLC Psychiatry
  • 相关文献

参考文献5

二级参考文献12

  • 1.中国药典2000年版 二部[S].,2000.附录VD.
  • 2GRADY M A, GASPERONI T L, KIRKPATRICK P. Aripiprazole [J] .Nat Rev Drug Discov,2003,2(6):427-428.
  • 3MALLIKAARJUN S,RIESGO Y,SALAZAR D E,et al. Time of dosing and food effect on aripiprazole pharmacokinetics. Psychotic disorders and antipsychotics[J].Eur Neuropsychopharmacol,2003,13(Suppl 4):332-333.
  • 4MALLIKAARJUN S,SALAZAR D E,BRAMER S L. Pharmacokinetics,tolerability,and safety of aripiprazole following multiple oral dosing in normal healthy volunteers[J].J Clin Pharmacol,2004,44(2):179-187.
  • 5Abilify(aripiprazole) tablets prescribing information[EB/OL].BristolMyers Squibb Company and Otsuka America Pharmaceutical Inc.2004,[2004-04-15].http://www.abilify.com.
  • 6MALLIKAARJUN S,TAMMARA B K,SALAZAR D E,et al. The effects of hepatic impairment on the pharmacokinetics of aripiprazole[J].Clin Pharmacol Ther,2002,71(2):66.
  • 7BRAMER S L,SHOAF S,SALAZAR D E,et al. Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole[J].Eur Neurosychopharmacol,2003,13(Suppl 4):333.
  • 8MALLIKAARJUN S, ALI M W,SALAZAR D E ,et al. The effect of age and gender on the pharmacokinetics of aripiprazole[J].Clin Pharmacol Ther ,2002,71(2):66-67.
  • 9SHIN I G,SOUKHOVA N,FLOCKHART D A.Effect of antipsychotic drugs on human liver cytochrome P-450(CYP) isoforms in vitro: preferential inhibition of CYP2D6[J].Drug Metab Dispos,1999,27(9):1078-1084.
  • 10瞿发林,王焕林.抗精神病药阿立哌唑(aripiprazole)[J].世界临床药物,2003,24(9):571-571. 被引量:14

共引文献13

同被引文献47

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部